CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 70 enrolled
Drug / intervention
adalimumab +1 moredrug
Likely dose
adalimumab 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01197144
NCT01197144N/ACompleted
CompareCT.gov

Pain Modulation in RA - Influence of Adalimumab. A Randomized, Placebo-controlled Study Using Functional Magnetic Resonance Imaging (PARADE)

Karolinska Institutet·interventional·Posted Sep 9, 2010·Updated Oct 22, 2020

In Brief

A clinical study evaluating adalimumab and Placebo for Arthritis, Rheumatoid and 2 related conditions. Completed, enrolled 70 participants across 2 sites.

Detailed Summary

The purpose of this study is to obtain increased knowledge concerning central pain and fatigue processing in rheumatoid arthritis, and how these conditions are influenced by treatment with Tumor Necrosis Factor (TNF) blockade with adalimumab.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsArthritis, Rheumatoid, Pain, Fatigue
CountriesSweden
CollaboratorsAbbott, Swedish Foundation for Strategic Research, The Swedish Research Council

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedSep 9, 2010
Enrollment StartOct 1, 2010
Primary CompletionNov 28, 2016
TodayJul 2, 2026
Enrollment to primary: 6.2 yearsPosted 15.8 years ago

Interventions

adalimumabdrug

Subcutaneous, 40 mg every other week for 4 weeks

Placebodrug

Subcutaneous, every other week for 4 weeks